Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...

Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with ...

Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 20 years by 2.66% on an annualized basis producing an average annual return of 11.48%. Currently, Gilead Sciences has a market ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

This was the stock's second consecutive day of gains.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.